Methods of treating glioblastoma in a subject informed by exosomal RNA signatures
The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).
1. A method of treating glioblastoma in a subject, the method comprising:
(1) determining the expression level of at least one gene selected from FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 and RP11-932O9.7, and the expression level of at least one reference gene in exosomal RNA extracted from a biological sample from the subject;
(2) normalizing the expression level of the at the least one gene by dividing the expression level of the at least one gene by the expression level of the at least one reference gene;
(3) determining that the normalized expression level of the at least one gene in the biological sample is greater than a corresponding predetermined cutoff value; and
(4) administering at least one therapeutically effective amount of dacomitinib to the subject.
2. The method of claim 1 , wherein the at least one gene comprises ZNF35.
3. The method of claim 1 , wherein the at least one reference gene comprises at least one gene selected from GAPDH, ACTB, VIM, EEF2, RPS2, RPS3, RPL15, RPL22, UBC, and NCL.
4. The method of claim 3 , wherein the at least one reference gene comprises GAPDH.
5. The method of claim 1 , wherein the biological sample is a blood, plasma, serum, urine or cerebrospinal fluid (CSF) sample.
6. The method of claim 1 , wherein determining the expression level of the at least one gene and the at least one reference gene in step (1) comprises using quantitative reverse transcription PCR or sequencing.
7. A method of treating glioblastoma in a subject, the method comprising:
(1) determining the expression level of at least one gene selected from tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, and NAA20, and the expression level of at least one reference gene in exosomal RNA extracted from a biological sample from the subject;
(2) normalizing the expression level of the at the least one gene by dividing the expression level of the at least one gene by the expression level of the at least one reference gene;
(3) determining that the normalized expression level of the at least one gene in the biological sample is less than a corresponding predetermined cutoff value; and
(4) administering at least one therapeutically effective amount of dacomitinib to the subject.
8. The method of claim 7 , wherein the at least one gene comprises LAMTOR2.
9. The method of claim 7 , wherein the at least one reference gene comprises at least one gene selected from GAPDH ACTB, VIM, EEF2, RPS2, RPS3, RPL15, RPL22, UBC, and NCL.
10. The method of claim 9 , wherein the at least one reference gene comprises GAPDH.
11. The method of claim 7 , wherein the biological sample is a blood, plasma, serum, urine or cerebrospinal fluid (C SF) sample.
12. The method of claim 7 , wherein determining the expression level of the at least one gene and the at least one reference gene in step (1) comprises using quantitative reverse transcription PCR or sequencing.
13. A method of treating glioblastoma in a subject, the method comprising:
(1) determining the expression level of at least one gene selected from CREBBP, CXCR2 and S100A9 and the expression level of at least one reference gene in exosomal RNA extracted from a biological sample isolated from the subject;
(2) normalizing the expression level of the at least one gene by dividing the expression level of the at least one gene by the expression level of the at least one reference gene;
(3) determining that the normalized expression level of the at least one gene is greater than a predetermined cutoff value; and
(4) administering at least one therapeutically effective amount of at least one glioblastoma therapy to the subject.
14. The method of claim 13 , wherein the at least one reference gene comprises at least one gene selected from GAPDH, ACTB, VIM, EEF2, RPS2, RPS3, RPL15, RPL22, UBC, and NCL.
15. The method of claim 14 , wherein the at least one reference gene comprises GAPDH.
16. The method of claim 13 , wherein the biological sample is a blood, plasma, serum, urine or cerebrospinal fluid (CSF) sample.
17. The method of claim 13 , wherein determining the expression level of the at least one gene and the at least one reference gene in step (1) comprises using quantitative reverse transcription PCR or sequencing.
18. The method of claim 13 , wherein the at least one glioblastoma therapy comprises administering to the subject at least one anti-cancer agent, radiation treatment, immunotherapy, surgery, radiation therapy, targeted therapy, hormone therapy, stem cell transplant or any combination thereof.